|
Alnylam Pharmaceuticals, Inc. (Alny) DCF -Bewertung
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Alnylam Pharmaceuticals, Inc. (ALNY) Bundle
Unabhängig davon, ob Sie ein Investor oder ein Analyst sind, ist dieser (ALNY) DCF-Taschenrechner Ihre Anlaufstelle für eine genaue Bewertung. Mit realen Daten von Alnylam Pharmaceuticals, Inc. geladen, können Sie Prognosen anpassen und die Auswirkungen sofort beobachten.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2020 |
AY2 2021 |
AY3 2022 |
AY4 2023 |
AY5 2024 |
FY1 2025 |
FY2 2026 |
FY3 2027 |
FY4 2028 |
FY5 2029 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 492.9 | 844.3 | 1,037.4 | 1,828.3 | 2,248.2 | 3,335.2 | 4,947.6 | 7,339.6 | 10,888.1 | 16,152.1 |
| Revenue Growth, % | 0 | 71.31 | 22.88 | 76.23 | 22.97 | 48.35 | 48.35 | 48.35 | 48.35 | 48.35 |
| EBITDA | -736.3 | -661.6 | -926.6 | -258.2 | -178.8 | -1,932.7 | -2,867.2 | -4,253.3 | -6,309.6 | -9,360.1 |
| EBITDA, % | -149.4 | -78.36 | -89.31 | -14.12 | -7.95 | -57.95 | -57.95 | -57.95 | -57.95 | -57.95 |
| Depreciation | 34.8 | 47.6 | 44.5 | 54.1 | 56.7 | 149.8 | 222.2 | 329.6 | 488.9 | 725.3 |
| Depreciation, % | 7.06 | 5.63 | 4.29 | 2.96 | 2.52 | 4.49 | 4.49 | 4.49 | 4.49 | 4.49 |
| EBIT | -771.1 | -709.1 | -971.0 | -312.3 | -235.5 | -2,035.5 | -3,019.5 | -4,479.3 | -6,644.9 | -9,857.5 |
| EBIT, % | -156.46 | -83.99 | -93.6 | -17.08 | -10.48 | -61.03 | -61.03 | -61.03 | -61.03 | -61.03 |
| Total Cash | 1,874.4 | 2,435.6 | 2,192.4 | 2,439.4 | 2,694.5 | 3,335.2 | 4,947.6 | 7,339.6 | 10,888.1 | 16,152.1 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 102.4 | 198.6 | 238.0 | 327.8 | 405.3 | 688.3 | 1,021.1 | 1,514.8 | 2,247.2 | 3,333.6 |
| Account Receivables, % | 20.78 | 23.52 | 22.94 | 17.93 | 18.03 | 20.64 | 20.64 | 20.64 | 20.64 | 20.64 |
| Inventories | 92.3 | 122.7 | 129.0 | 89.1 | 78.5 | 360.6 | 534.9 | 793.6 | 1,177.2 | 1,746.4 |
| Inventories, % | 18.73 | 14.53 | 12.43 | 4.88 | 3.49 | 10.81 | 10.81 | 10.81 | 10.81 | 10.81 |
| Accounts Payable | 52.0 | 73.4 | 98.1 | 55.5 | 88.4 | 237.9 | 352.9 | 523.5 | 776.7 | 1,152.1 |
| Accounts Payable, % | 10.54 | 8.7 | 9.46 | 3.04 | 3.93 | 7.13 | 7.13 | 7.13 | 7.13 | 7.13 |
| Capital Expenditure | -70.4 | -76.4 | -72.1 | -62.2 | -34.3 | -234.8 | -348.3 | -516.6 | -766.4 | -1,137.0 |
| Capital Expenditure, % | -14.28 | -9.05 | -6.95 | -3.4 | -1.52 | -7.04 | -7.04 | -7.04 | -7.04 | -7.04 |
| Tax Rate, % | -55.45 | -55.45 | -55.45 | -55.45 | -55.45 | -55.45 | -55.45 | -55.45 | -55.45 | -55.45 |
| EBITAT | -773.5 | -709.7 | -974.6 | -317.1 | -366.1 | -2,035.5 | -3,019.5 | -4,479.3 | -6,644.9 | -9,857.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -951.9 | -843.6 | -1,023.2 | -417.9 | -377.7 | -2,536.1 | -3,537.7 | -5,248.1 | -7,785.3 | -11,549.2 |
| WACC, % | 5.88 | 5.88 | 5.88 | 5.88 | 5.88 | 5.88 | 5.88 | 5.88 | 5.88 | 5.88 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -24,842.9 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -11,780 | |||||||||
| Terminal Value | -303,300 | |||||||||
| Present Terminal Value | -227,887 | |||||||||
| Enterprise Value | -252,730 | |||||||||
| Net Debt | -127 | |||||||||
| Equity Value | -252,603 | |||||||||
| Diluted Shares Outstanding, MM | 129 | |||||||||
| Equity Value Per Share | -1,964.41 |
What You Will Get
- Real Alnylam Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Alnylam’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Comprehensive Financial Data: Gain access to precise historical data and future forecasts for Alnylam Pharmaceuticals, Inc. (ALNY).
- Adjustable Forecast Parameters: Modify highlighted cells for key metrics such as WACC, growth rates, and profit margins.
- Real-Time Calculations: Automatic recalculations for DCF, Net Present Value (NPV), and cash flow assessments.
- Interactive Dashboard: User-friendly charts and summaries to help visualize valuation outcomes.
- Designed for All Skill Levels: An intuitive layout tailored for investors, financial officers, and consultants alike.
How It Works
- Download: Get the pre-configured Excel file containing Alnylam Pharmaceuticals' financial data.
- Customize: Modify projections such as revenue growth, EBITDA %, and WACC as needed.
- Update Automatically: Watch the intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Develop various projections and analyze results immediately.
- Make Decisions: Leverage the valuation findings to inform your investment strategy for Alnylam Pharmaceuticals, Inc. (ALNY).
Why Choose This Calculator for Alnylam Pharmaceuticals, Inc. (ALNY)?
- Accurate Data: Up-to-date Alnylam financials provide trustworthy valuation outcomes.
- Customizable: Modify essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Ready-to-use calculations save you from starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants focused on biotechnology.
- User-Friendly: Clear layout and guided instructions ensure ease of use for everyone.
Who Should Use This Product?
- Healthcare Investors: Develop comprehensive and accurate valuation models for investment decisions in biotech.
- Corporate Strategy Teams: Evaluate valuation scenarios to inform strategic initiatives within the organization.
- Consultants and Advisors: Deliver precise valuation insights for Alnylam Pharmaceuticals, Inc. (ALNY) to clients.
- Students and Educators: Utilize real-world data to enhance learning and practice in financial modeling.
- Biotech Enthusiasts: Gain insights into how companies like Alnylam Pharmaceuticals, Inc. (ALNY) are valued in the healthcare market.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Alnylam Pharmaceuticals historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Alnylam Pharmaceuticals, Inc. (ALNY).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.